Skip to content

    ARROWHEAD PHARMACEUTICALS (ARWR) stock price & financials

    View ARWR earnings calls

    Overview

    Price

    Market Cap

    Sector

    Rank

    Performance+289.7% 1Y

    Financials

    Income Statement

    Financial Trajectories

    11
    Quarterly
    MetricQ3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Trend
    EarningsRevenue
    $0
    $2.50M
    $542.71M
    $27.77M
    $256.47M
    $264.03M
    +10461.3%
    $73.74M
    -86.4%
    $75.25M
    +171.0%
    Strengthening
    Operating Profit
    -$162.20M
    -$161.41M
    $381.20M
    -$165.55M
    $44.11M
    $40.81M
    -$141.26M
    -137.1%
    -$170.09M
    -2.7%
    Weakening
    Net Profit
    -$170.54M
    -$173.09M
    $370.44M
    -$175.24M
    -$23.75M
    +86.1%
    $30.81M
    -$132.73M
    -135.8%
    -$194.28M
    -10.9%
    Weakening
    EPS
    $-1.39
    $2.78
    $-1.26
    $0.22
    $-0.93
    -133.5%
    $-1.36
    -7.9%
    Weakening
    Other Income
    -$10.60M
    -$13.70M
    -$11.59M
    -$13.54M
    -$7.99M
    +24.6%
    -$12.54M
    +8.5%
    $3.69M
    -$8.81M
    +34.9%
    Strengthening
    Interest
    $14.65M
    $21.65M
    $21.64M
    $24.38M
    $21.69M
    +48.1%
    $22.50M
    +4.0%
    $23.85M
    +10.2%
    $24.56M
    +0.7%
    Strengthening
    Depreciation
    Profit before Tax
    -$172.80M
    -$175.12M
    $369.62M
    -$179.09M
    $36.12M
    $28.27M
    -$137.56M
    -137.2%
    -$178.91M
    +0.1%
    Weakening
    MarginsOPM
    -6456.5%
    70.2%
    -596.2%
    17.2%
    15.5%
    -191.6%
    -372.7%
    -226.0%
    +62.1%
    Weakening
    Tax
    -0.3%
    -0.1%
    0.5%
    0.2%
    55.4%
    0.1%
    -0.0%
    -102.1%
    -0.0%
    -104.2%
    Weakening
    ReturnsROIC
    8.9%
    9.0%
    -19.3%
    9.1%
    1.2%
    -86.1%
    -1.6%
    -117.8%
    6.9%
    10.1%
    +10.9%
    Weakening

    Balance Sheet

    Balance Sheet

    USD · Annual
    Line itemFY18FY19FY20FY21FY22FY23FY24FY25TTM
    AssetsCash & Equivalents$30.13M$221.80M$143.58M$184.43M$108.00M$110.89M$102.69M$226.55M$54.76M
    Short-Term Investments$85.02M$126.73M$0
    Total Current Assets$78.77M$265.25M$322.37M$384.60M$405.30M$416.47M$695.47M$950.64M$1.67B
    Net PP&E$13.94M$23.21M$47.02M$66.02M$168.59M$335.56M$431.29M$426.41M$428.97M
    Goodwill
    Intangibles$18.76M$17.06M$15.36M$13.66M$11.96M$10.26M$8.56M$6.86M$5.59M
    Total Assets$111.61M$349.85M$522.50M$710.15M$691.94M$765.55M$1.14B$1.39B$2.11B
    LiabilitiesTotal Current Liabilities$12.36M$97.07M$40.68M$146.54M$138.85M$105.46M$103.17M$195.49M$283.35M
    Short-Term Debt
    Long-Term Debt
    Long-Term Leases$20.04M$23.30M$78.80M$104.61M$111.03M$104.11M$114.30M
    Total Liabilities$16.37M$105.81M$60.73M$301.33M$273.60M$478.39M$948.74M$881.88M$1.65B
    EquityCommon Stock & APIC$180.9K$187.9K$195.0K$197.0K$198.0K$200.0K$217.0K$231.0K$237.0K
    Retained Earnings-$487.27M-$419.29M-$503.84M-$644.69M-$820.75M-$1.03B-$1.63B-$1.63B-$1.92B
    Total Equity$95.80M$244.59M$461.78M$408.82M$398.52M$271.34M$185.44M$466.05M$465.53M
    HighlightsNet Cash / (Debt)

    Cash Flow

    Cash Flow

    USD · Annual
    Line itemFY18FY19FY20FY21FY22FY23FY24FY25TTM
    ActivitiesCash from Operating-$47.22M$173.03M-$95.80M$171.31M-$136.13M-$153.89M-$462.85M$179.55M-$59.05M
    Cash from Investing-$7.43M-$47.75M-$240.78M-$141.68M-$5.42M-$96.16M-$420.07M-$129.29M-$801.72M
    Cash from Financing$59.95M$66.38M$257.95M$11.30M$65.19M$253.05M$870.52M$74.01M$784.19M
    SummaryCapital Expenditure-$1.42M-$12.00M-$11.95M-$23.57M-$52.78M-$176.74M-$141.47M-$22.67M-$16.06M
    Free Cash Flow-$48.64M$161.03M-$107.75M$147.75M-$188.91M-$330.63M-$604.32M$156.89M-$75.11M
    FCF Margin-301.3%95.4%-122.5%106.8%-77.7%-137.3%-17018.3%18.9%-11.2%

    Ratios